The biopharmaceutical industry in China, like the rest of the world, was forced to swiftly adopt decentralized clinical trial (DCT) approaches to maintain progress during to the COVID-19 pandemic. And, like the rest of the world, its patients, investigators and sponsors were hopeful about the benefits of using these tools.
Two new surveys conducted by IQVIA in China found patients are overwhelmingly open to participating in fully decentralized as well as hybrid virtual trials, and to using wearables, electronic data collection and other digital tools as part of that experience.